The present data about the treatment of progressive CHP are few and largely based on observational studies and expert opinion. It is suggested that pirfenidone may slow disease progression in cases of CHP as it has some anti-inflammatory in addition to antifibrotic effects, so this study aimed to evaluate the efficacy of pirfenidone in chronic hypersensitivity pneumonitis. This study included 40 adult patients (≥ 18 years) with a diagnosis of chronic progressive hypersensitivity pneumonitis. The included patients were divided into 2 groups 20 patients in each one. Group 1 received pirfenidone in addition to the conventional treatment Group 2 was maintained on conventional treatment. Forced vital capacity (FVC), 6-min walking test (6MWT), oxygen tension in the arterial blood (PaO2), and St. George’s Respiratory Questionnaire (SGRQ) were measured before and after 6 months of a pirfenidone treatment trial. The present study showed that in patients with progressive chronic hypersensitivity pneumonitis, adding pirfenidone to their conventional treatment was associated with significantly higher FVC, 6MWT, SaO2, and PaO2, and significant lower SGRQ score compared to patients who were maintained only on their conventional treatment at 6 months after treatment Pirfenidone can reduce the progression of chronic hypersensitivity pneumonitis and so it can be considered a therapeutic option in its treatment. ClinicalTrials.gov, NCT04675619 .

中文翻译：

---

吡非尼酮治疗进行性慢性超敏性肺炎的疗效评估

目前关于进行性CHP治疗的数据很少，并且主要基于观察研究和专家意见。由于吡非尼酮除具有抗纤维化作用外还具有抗炎作用，因此它在CHP病例中可能会减慢疾病的进展，因此本研究旨在评估吡非尼酮在慢性超敏性肺炎中的疗效。这项研究纳入了40位诊断为慢性进行性超敏性肺炎的成年患者（≥18岁）。纳入患者分为两组，每组20例。除常规治疗外，第1组接受吡非尼酮治疗。第2组保持常规治疗。强制肺活量（FVC），6分钟步行测试（6MWT），动脉血中的氧气张力（PaO2）和 在进行吡非尼酮治疗试验的6个月前后，测量了乔治的呼吸问卷（SGRQ）。本研究表明，在进行性慢性超敏性肺炎的患者中，与仅接受常规治疗的患者相比，在传统治疗中添加吡非尼酮与FVC，6MWT，SaO2和PaO2显着相关，并且SGRQ评分显着较低。治疗后6个月吡非尼酮可以减少慢性超敏性肺炎的进展，因此可以考虑将其作为治疗的选择。ClinicalTrials.gov，NCT04675619。与仅在治疗后6个月仅接受常规治疗的患者相比，在常规治疗中添加吡非尼酮与FVC，6MWT，SaO2和PaO2显着升高相关，并且SGRQ得分显着降低。吡非尼酮可以减少慢性超敏性肺炎的进展因此，可以将其视为治疗的一种治疗选择。ClinicalTrials.gov，NCT04675619。与仅在治疗后6个月仅接受常规治疗的患者相比，在常规治疗中添加吡非尼酮与FVC，6MWT，SaO2和PaO2显着升高相关，并且SGRQ得分显着降低。吡非尼酮可以减少慢性超敏性肺炎的进展因此，可以将其视为治疗的一种治疗选择。ClinicalTrials.gov，NCT04675619。